210 related articles for article (PubMed ID: 16964222)
1. Impact of microarray data quality on genomic data submissions to the FDA.
Frueh FW
Nat Biotechnol; 2006 Sep; 24(9):1105-7. PubMed ID: 16964222
[No Abstract] [Full Text] [Related]
2. A framework for the use of genomics data at the EPA.
Dix DJ; Gallagher K; Benson WH; Groskinsky BL; McClintock JT; Dearfield KL; Farland WH
Nat Biotechnol; 2006 Sep; 24(9):1108-11. PubMed ID: 16964223
[No Abstract] [Full Text] [Related]
3. Data quality in genomics and microarrays.
Ji H; Davis RW
Nat Biotechnol; 2006 Sep; 24(9):1112-3. PubMed ID: 16964224
[TBL] [Abstract][Full Text] [Related]
4. Empowering microarrays in the regulatory setting.
Casciano DA; Woodcock J
Nat Biotechnol; 2006 Sep; 24(9):1103. PubMed ID: 16964221
[No Abstract] [Full Text] [Related]
5. Making the most of microarrays.
Nat Biotechnol; 2006 Sep; 24(9):1039. PubMed ID: 16964193
[No Abstract] [Full Text] [Related]
6. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
7. QA/QC issues to aid regulatory acceptance of microarray gene expression data.
Fuscoe JC; Tong W; Shi L
Environ Mol Mutagen; 2007 Jun; 48(5):349-53. PubMed ID: 17567852
[TBL] [Abstract][Full Text] [Related]
8. Genomics and medical devices: a new paradigm for health care.
Rados C
FDA Consum; 2005; 39(6):34-9. PubMed ID: 16669116
[No Abstract] [Full Text] [Related]
9. Microarrays: quality control.
Eisenstein M
Nature; 2006 Aug; 442(7106):1067-70. PubMed ID: 16943838
[No Abstract] [Full Text] [Related]
10. The need for standards, not guidelines, in biological data reporting and sharing.
Burgoon LD
Nat Biotechnol; 2006 Nov; 24(11):1369-73. PubMed ID: 17093486
[TBL] [Abstract][Full Text] [Related]
11. Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential.
Shi L; Perkins RG; Fang H; Tong W
Curr Opin Biotechnol; 2008 Feb; 19(1):10-8. PubMed ID: 18155896
[TBL] [Abstract][Full Text] [Related]
12. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
13. Microarray data--the US FDA, industry and academia.
Hackett JL; Lesko LJ
Nat Biotechnol; 2003 Jul; 21(7):742-3. PubMed ID: 12833089
[No Abstract] [Full Text] [Related]
14. MIAME guidelines.
Knudsen TB; Daston GP;
Reprod Toxicol; 2005; 19(3):263. PubMed ID: 15686863
[No Abstract] [Full Text] [Related]
15. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program.
Orr MS; Goodsaid F; Amur S; Rudman A; Frueh FW
Clin Pharmacol Ther; 2007 Feb; 81(2):294-7. PubMed ID: 17259954
[TBL] [Abstract][Full Text] [Related]
16. Correlation analysis of external RNA controls reveals its utility for assessment of microarray assay.
Fan X; Fang H; Hong H; Perkins R; Shi L; Tong W
Anal Biochem; 2009 Feb; 385(2):203-7. PubMed ID: 19059192
[TBL] [Abstract][Full Text] [Related]
17. New FDA guidance on electronic records and signatures.
Donawa M
Med Device Technol; 2001 Nov; 12(9):32-5. PubMed ID: 12938536
[TBL] [Abstract][Full Text] [Related]
18. Errors in patent application sequence listings.
Jones R
Nat Biotechnol; 2003 Oct; 21(10):1239-40. PubMed ID: 14520406
[No Abstract] [Full Text] [Related]
19. Trying to improve their image. But FDA scanning hearing reveals regulatory void.
Rhea S
Mod Healthc; 2010 Apr; 40(14):14. PubMed ID: 20405553
[No Abstract] [Full Text] [Related]
20. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
